Publications by authors named "W R Selman"

Article Synopsis
  • - The study investigated the link between neurocognitive performance and blood levels of GluA1 autoantibodies in NCAA athletes, comparing contact and noncontact sport participants before and after the season.
  • - Contact sport athletes showed a significant increase in serum GluA1 autoantibodies at the end of the season, regardless of concussion status, while noncontact athletes did not exhibit any changes.
  • - Athletes with higher levels of GluA1 autoantibodies had poorer reaction times, indicating cognitive impairment, which suggests that these autoantibodies could serve as a blood-based marker to identify athletes at risk for cognitive issues, even without a concussion.
View Article and Find Full Text PDF

The objective of this investigation was to find out whether L-carnitine-loaded nanoparticle (LCn) could reduce the reproductive toxicity of cypermethrin (CYP), the widely used insecticide in veterinary medicine in male rats. Twenty male Wistar rats that weighed between 210 and 240 g were split into four groups and treated daily for 2 months. The control group was given 0.

View Article and Find Full Text PDF

Malaria-causing parasites have a complex life cycle and present numerous antigen targets that may contribute to protective immune responses. The currently recommended vaccine-RTS,S-functions by targeting the Plasmodium falciparum circumsporozoite protein (CSP), which is the most abundant surface protein of the sporozoite form responsible for initiating infection of the human host. Despite showing only moderate efficacy, RTS,S has established a strong foundation for the development of next-generation subunit vaccines.

View Article and Find Full Text PDF

Traumatic brain injury (TBI) is a major risk factor for several neurodegenerative disorders, including Parkinson's disease (PD) and Alzheimer's disease (AD). Neuroinflammation is a cause of later secondary cell death following TBI, has the potential to aggravate the initial impact, and provides a therapeutic target, albeit that has failed to translate into clinical trial success. Thalidomide-like compounds have neuroinflammation reduction properties across cellular and animal models of TBI and neurodegenerative disorders.

View Article and Find Full Text PDF